天津医药 ›› 2022, Vol. 50 ›› Issue (9): 959-964.doi: 10.11958/20211522
李国旭1,2,3(), 王萍4, 周伟玮1,3, 崔晓玉1,3, 张芳1, 舒剑波4, 刘洋1,△(
)
收稿日期:
2021-07-05
修回日期:
2021-10-19
出版日期:
2022-09-15
发布日期:
2022-09-05
通讯作者:
刘洋
E-mail:etyylgx@163.com;etyyly@163.com
作者简介:
李国旭(1993),男,住院医师,主要从事新生儿危重症、感染性疾患及出生缺陷方面研究。E-mail: 基金资助:
LI Guoxu1,2,3(), WANG Ping4, ZHOU Weiwei1,3, CUI Xiaoyu1,3, ZHANG Fang1, SHU Jianbo4, LIU Yang1,△(
)
Received:
2021-07-05
Revised:
2021-10-19
Published:
2022-09-15
Online:
2022-09-05
Contact:
LIU Yang
E-mail:etyylgx@163.com;etyyly@163.com
李国旭, 王萍, 周伟玮, 崔晓玉, 张芳, 舒剑波, 刘洋. 足月新生儿黄疸与维生素D及NADSYN1基因多态性的相关性研究[J]. 天津医药, 2022, 50(9): 959-964.
LI Guoxu, WANG Ping, ZHOU Weiwei, CUI Xiaoyu, ZHANG Fang, SHU Jianbo, LIU Yang. Correlation between jaundice and vitamin D and NADSYN1 gene polymorphism in full-term neonates[J]. Tianjin Medical Journal, 2022, 50(9): 959-964.
摘要:
目的 研究足月新生儿黄疸、维生素D(VD)水平及NADSYN1基因rs12785878位点单核苷酸多态性(SNP)间的关系。方法 回顾性分析216例患有黄疸的足月新生儿的临床资料,利用液相色谱-串联质谱法(LC-MS/MS)检测血清VD水平,高分辨熔解曲线(HRM)分析NADSYN1基因rs12785878位点SNP。以患儿是否>14 d分组并分别分析高胆红素血症的影响因素。结果 对于≤14 d患儿,感染、剖宫产、母乳喂养为高胆红素血症发生的危险因素;对于>14 d患儿,感染、低血浆蛋白为高胆红素血症发生的危险因素。建立的rs12785878位点HRM方法扩增反应良好,GG、GT、TT基因型区分明显。高胆组患儿携带GG基因型、G等位基因的比例更高。≤14 d患儿,TT基因型新生儿VD水平高于GG基因型新生儿[(12.61±5.23)μg/L vs.(9.62±4.24)μg/L,P<0.05]。结论 NADSYN1基因rs12785878位点GG基因型为高胆红素血症、≤14 d新生儿低VD水平的危险因素,可作为足月新生儿高胆红素血症诊治的新参考。
中图分类号:
组别 | n | 男婴 | 日龄(d) | 出生体质量(g) | 妊娠天数(d) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
对照组1 | 60 | 37(61.7) | 4(1,12) | 3 372±408 | 278(268,283) | |||||||||||
高胆组1 | 44 | 23(52.3) | 7(5,10) | 3 351±412 | 274(270,280) | |||||||||||
χ2、Z或t | 0.918 | 1.824 | 0.251 | 1.456 | ||||||||||||
组别 | 胎次:G1P1 | 剖宫产 | 血pH | 血清VD(μg/L) | ||||||||||||
对照组1 | 31(51.7) | 31(51.7) | 7.40(7.35,7.46) | 12.1±5.6 | ||||||||||||
高胆组1 | 17(38.6) | 33(75.0) | 7.40(7.38,7.46) | 10.9±3.7 | ||||||||||||
χ2、Z或t | 1.734 | 5.839* | 0.862 | 1.232 | ||||||||||||
组别 | TBIL (μmol/L) | 孕母年龄 (岁) | 孕母受教育程度 (大专及以上) | 母乳 喂养 | ||||||||||||
对照组1 | 160.4±32.8 | 29.4±4.4 | 37(61.7) | 31(51.7) | ||||||||||||
高胆组1 | 280.0±55.2 | 28.7±4.1 | 31(70.5) | 36(81.8) | ||||||||||||
χ2、Z或t | 12.814** | 0.813 | 0.866 | 10.096** | ||||||||||||
组别 | 感染 | 血糖 (mmol/L) | 血浆蛋白 (g/L) | 白蛋白 (g/L) | ||||||||||||
对照组1 | 6(10.0) | 4.82±0.87 | 54.0(51.1,57.0) | 38.2(35.8,40.1) | ||||||||||||
高胆组1 | 15(34.1) | 5.15±1.22 | 51.9(49.9,54.9) | 38.7(36.9,41.1) | ||||||||||||
χ2、Z或t | 9.142** | 1.604 | 2.201* | 1.033 |
表1 ≤14 d新生儿高胆组与对照组的临床资料比较
Tab.1 Comparison of clinical data between the hyperbilirubinemia group and the control group in neonates with jaundice ≤14 d
组别 | n | 男婴 | 日龄(d) | 出生体质量(g) | 妊娠天数(d) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
对照组1 | 60 | 37(61.7) | 4(1,12) | 3 372±408 | 278(268,283) | |||||||||||
高胆组1 | 44 | 23(52.3) | 7(5,10) | 3 351±412 | 274(270,280) | |||||||||||
χ2、Z或t | 0.918 | 1.824 | 0.251 | 1.456 | ||||||||||||
组别 | 胎次:G1P1 | 剖宫产 | 血pH | 血清VD(μg/L) | ||||||||||||
对照组1 | 31(51.7) | 31(51.7) | 7.40(7.35,7.46) | 12.1±5.6 | ||||||||||||
高胆组1 | 17(38.6) | 33(75.0) | 7.40(7.38,7.46) | 10.9±3.7 | ||||||||||||
χ2、Z或t | 1.734 | 5.839* | 0.862 | 1.232 | ||||||||||||
组别 | TBIL (μmol/L) | 孕母年龄 (岁) | 孕母受教育程度 (大专及以上) | 母乳 喂养 | ||||||||||||
对照组1 | 160.4±32.8 | 29.4±4.4 | 37(61.7) | 31(51.7) | ||||||||||||
高胆组1 | 280.0±55.2 | 28.7±4.1 | 31(70.5) | 36(81.8) | ||||||||||||
χ2、Z或t | 12.814** | 0.813 | 0.866 | 10.096** | ||||||||||||
组别 | 感染 | 血糖 (mmol/L) | 血浆蛋白 (g/L) | 白蛋白 (g/L) | ||||||||||||
对照组1 | 6(10.0) | 4.82±0.87 | 54.0(51.1,57.0) | 38.2(35.8,40.1) | ||||||||||||
高胆组1 | 15(34.1) | 5.15±1.22 | 51.9(49.9,54.9) | 38.7(36.9,41.1) | ||||||||||||
χ2、Z或t | 9.142** | 1.604 | 2.201* | 1.033 |
因素 | B | SE | Wald χ2 | P | OR | OR 95%CI |
---|---|---|---|---|---|---|
剖宫产 | 1.018 | 0.492 | 4.285 | 0.038 | 2.766 | 1.056~7.250 |
母乳喂养 | 1.483 | 0.538 | 7.604 | 0.006 | 4.405 | 1.536~12.639 |
感染 | 1.906 | 0.641 | 8.848 | 0.003 | 6.727 | 1.916~23.622 |
血浆蛋白 | -0.080 | 0.057 | 2.013 | 0.156 | 0.923 | 0.826~1.031 |
血清VD | -0.032 | 0.050 | 0.398 | 0.528 | 0.969 | 0.878~1.069 |
常数项 | 2.318 | 3.094 | 0.561 | 0.454 | 10.154 |
表2 ≤14 d新生儿发生高胆红素血症的影响因素分析
Tab.2 Analysis of risk factors of hyperbilirubinemia in neonates ≤14 d
因素 | B | SE | Wald χ2 | P | OR | OR 95%CI |
---|---|---|---|---|---|---|
剖宫产 | 1.018 | 0.492 | 4.285 | 0.038 | 2.766 | 1.056~7.250 |
母乳喂养 | 1.483 | 0.538 | 7.604 | 0.006 | 4.405 | 1.536~12.639 |
感染 | 1.906 | 0.641 | 8.848 | 0.003 | 6.727 | 1.916~23.622 |
血浆蛋白 | -0.080 | 0.057 | 2.013 | 0.156 | 0.923 | 0.826~1.031 |
血清VD | -0.032 | 0.050 | 0.398 | 0.528 | 0.969 | 0.878~1.069 |
常数项 | 2.318 | 3.094 | 0.561 | 0.454 | 10.154 |
组别 | n | 男婴 | 日龄(d) | 出生体质量(g) | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
对照组2 | 60 | 28(46.7) | 25.0(18.0,29.8) | 3 332±368 | |||||||||||||
高胆组2 | 52 | 29(55.8) | 23.5(20.3,29.0) | 3 226±430 | |||||||||||||
χ2、Z或t | 0.924 | 0.368 | 1.410 | ||||||||||||||
组别 | 妊娠天数(d) | 胎次:G1P1 | 剖宫产 | 母乳喂养 | 感染 | ||||||||||||
对照组2 | 278(272,281) | 21(35.0) | 26(43.3) | 52(86.7) | 6(10.0) | ||||||||||||
高胆组2 | 271(268,277) | 18(34.6) | 24(46.2) | 48(92.3) | 16(30.8) | ||||||||||||
χ2、Z或t | 2.759* | 0.002 | 0.090 | 0.927 | 7.613* | ||||||||||||
组别 | 血糖 (mmol/L) | 血浆蛋白(g/L) | 白蛋白 (g/L) | 血pH | |||||||||||||
对照组2 | 5.03(4.58,5.41) | 55.4±3.9 | 39.9(37.8,41.0) | 7.42±0.07 | |||||||||||||
高胆组2 | 4.81(4.19,5.47) | 52.0±3.1 | 39.1(37.7,41.2) | 7.42±0.08 | |||||||||||||
χ2、Z或t | 0.321 | 5.034** | 0.426 | 0.124 | |||||||||||||
组别 | 血清VD (μg/L) | TBIL (μmol/L) | 母亲年 龄(岁) | 母亲受教育程度 (大专及以上) | |||||||||||||
对照组2 | 19.71±9.04 | 23.2(19.2,27.9) | 29.1±4.4 | 33(55.0) | |||||||||||||
高胆组2 | 16.36±7.04 | 162.4(133.6,227.7) | 30.5±4.0 | 31(59.6) | |||||||||||||
χ2、Z或t | 2.202* | 8.420** | 1.710 | 0.242 |
表3 >14 d新生儿高胆组与对照组的临床资料比较
Tab.3 Comparison of clinical data between the hyperbilirubinemia group and the control group in neonates with jaundice >14 d
组别 | n | 男婴 | 日龄(d) | 出生体质量(g) | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
对照组2 | 60 | 28(46.7) | 25.0(18.0,29.8) | 3 332±368 | |||||||||||||
高胆组2 | 52 | 29(55.8) | 23.5(20.3,29.0) | 3 226±430 | |||||||||||||
χ2、Z或t | 0.924 | 0.368 | 1.410 | ||||||||||||||
组别 | 妊娠天数(d) | 胎次:G1P1 | 剖宫产 | 母乳喂养 | 感染 | ||||||||||||
对照组2 | 278(272,281) | 21(35.0) | 26(43.3) | 52(86.7) | 6(10.0) | ||||||||||||
高胆组2 | 271(268,277) | 18(34.6) | 24(46.2) | 48(92.3) | 16(30.8) | ||||||||||||
χ2、Z或t | 2.759* | 0.002 | 0.090 | 0.927 | 7.613* | ||||||||||||
组别 | 血糖 (mmol/L) | 血浆蛋白(g/L) | 白蛋白 (g/L) | 血pH | |||||||||||||
对照组2 | 5.03(4.58,5.41) | 55.4±3.9 | 39.9(37.8,41.0) | 7.42±0.07 | |||||||||||||
高胆组2 | 4.81(4.19,5.47) | 52.0±3.1 | 39.1(37.7,41.2) | 7.42±0.08 | |||||||||||||
χ2、Z或t | 0.321 | 5.034** | 0.426 | 0.124 | |||||||||||||
组别 | 血清VD (μg/L) | TBIL (μmol/L) | 母亲年 龄(岁) | 母亲受教育程度 (大专及以上) | |||||||||||||
对照组2 | 19.71±9.04 | 23.2(19.2,27.9) | 29.1±4.4 | 33(55.0) | |||||||||||||
高胆组2 | 16.36±7.04 | 162.4(133.6,227.7) | 30.5±4.0 | 31(59.6) | |||||||||||||
χ2、Z或t | 2.202* | 8.420** | 1.710 | 0.242 |
因素 | B | SE | Wald χ2 | P | OR | OR 95%CI |
---|---|---|---|---|---|---|
妊娠天数 | -0.056 | 0.031 | 3.177 | 0.075 | 0.946 | 0.890~1.006 |
感染 | 1.519 | 0.617 | 6.069 | 0.014 | 4.569 | 1.364~15.301 |
血浆蛋白 | -0.242 | 0.073 | 11.055 | 0.001 | 0.785 | 0.681~0.905 |
血清VD | -0.029 | 0.030 | 0.938 | 0.333 | 0.971 | 0.916~1.030 |
常数项 | 28.296 | 9.230 | 9.398 | 0.002 | 0.000 |
表4 >14 d新生儿发生高胆红素血症的影响因素分析
Tab.4 Analysis of risk factors of hyperbilirubinemia in neonates >14 d
因素 | B | SE | Wald χ2 | P | OR | OR 95%CI |
---|---|---|---|---|---|---|
妊娠天数 | -0.056 | 0.031 | 3.177 | 0.075 | 0.946 | 0.890~1.006 |
感染 | 1.519 | 0.617 | 6.069 | 0.014 | 4.569 | 1.364~15.301 |
血浆蛋白 | -0.242 | 0.073 | 11.055 | 0.001 | 0.785 | 0.681~0.905 |
血清VD | -0.029 | 0.030 | 0.938 | 0.333 | 0.971 | 0.916~1.030 |
常数项 | 28.296 | 9.230 | 9.398 | 0.002 | 0.000 |
组别 | n | GG | TG | TT | χ2 | P |
---|---|---|---|---|---|---|
对照组 | 120 | 22(19) | 52(58) | 46(43) | 0.648 | 0.723 |
高胆组 | 96 | 32(33) | 49(46) | 15(16) | 0.137 | 0.934 |
表5 rs12785878位点基因型Hardy-Weinberg平衡检测 [实际值(理论值)]
Tab.5 Hardy-Weinberg Equilibrium test at rs12785878
组别 | n | GG | TG | TT | χ2 | P |
---|---|---|---|---|---|---|
对照组 | 120 | 22(19) | 52(58) | 46(43) | 0.648 | 0.723 |
高胆组 | 96 | 32(33) | 49(46) | 15(16) | 0.137 | 0.934 |
组别 | n | 基因型[例(%)] | 等位基因[频次(%)] | |||
---|---|---|---|---|---|---|
TT | TG | GG | T | G | ||
≤14 d组 | ||||||
对照组1 | 60 | 23(38.3) | 24(40.0) | 13(21.7) | 70(58.3) | 50(41.7) |
高胆组1 | 44 | 7(15.9) | 22(50.0) | 15(34.1) | 36(40.9) | 52(59.1) |
χ2 | 6.454* | 6.618* | ||||
>14 d组 | ||||||
对照组2 | 60 | 23(38.3) | 28(46.7) | 9(15.0) | 74(61.7) | 46(38.3) |
高胆组2 | 52 | 8(15.4) | 27(51.9) | 17(32.7) | 43(41.3) | 61(58.7) |
χ2 | 9.213* | 9.221* |
表6 高胆组与对照组rs12785878位点基因型比较
Tab.6 Comparison of rs12785878 genotype between the hyperbilirubinemia group and the control group
组别 | n | 基因型[例(%)] | 等位基因[频次(%)] | |||
---|---|---|---|---|---|---|
TT | TG | GG | T | G | ||
≤14 d组 | ||||||
对照组1 | 60 | 23(38.3) | 24(40.0) | 13(21.7) | 70(58.3) | 50(41.7) |
高胆组1 | 44 | 7(15.9) | 22(50.0) | 15(34.1) | 36(40.9) | 52(59.1) |
χ2 | 6.454* | 6.618* | ||||
>14 d组 | ||||||
对照组2 | 60 | 23(38.3) | 28(46.7) | 9(15.0) | 74(61.7) | 46(38.3) |
高胆组2 | 52 | 8(15.4) | 27(51.9) | 17(32.7) | 43(41.3) | 61(58.7) |
χ2 | 9.213* | 9.221* |
基因型 | n | ≤14 d组VD水平 | n | >14 d组VD水平 |
---|---|---|---|---|
GG型 | 28 | 9.62±4.24 | 26 | 17.28±7.57 |
TG型 | 46 | 12.05±4.81a | 55 | 17.79±8.30 |
TT型 | 30 | 12.61±5.23a | 31 | 19.53±9.00 |
F | 3.239* | 0.621 |
表7 rs12785878位点不同基因型及等位基因VD水平的比较 (μg/L,$\bar{x}±s$)
Tab.7 Comparison of VD levels between neonates with different genotypes at RS12785878 locus
基因型 | n | ≤14 d组VD水平 | n | >14 d组VD水平 |
---|---|---|---|---|
GG型 | 28 | 9.62±4.24 | 26 | 17.28±7.57 |
TG型 | 46 | 12.05±4.81a | 55 | 17.79±8.30 |
TT型 | 30 | 12.61±5.23a | 31 | 19.53±9.00 |
F | 3.239* | 0.621 |
[1] | ZAHED PASHA Y, ALIZADEH-TABARI S, ZAHED PASHA E, et al. Etiology and therapeutic management of neonatal jaundice in Iran:a systematic review and meta-analysis[J]. World J Pediatr, 2020, 16(5):480-493. doi: 10.1007/s12519-020-00339-3. |
[2] | SHAPIRO S M, RIORDAN S M. Review of bilirubin neurotoxicity II:preventing and treating acute bilirubin encephalopathy and kernicterus spectrum disorders[J]. Pediatr Res, 2020, 87(2):332-337. doi: 10.1038/s41390-019-0603-5. |
[3] | MAILHOT G, WHITE J H. Vitamin D and immunity in infants and children[J]. Nutrients, 2020, 12(5):1233. doi: 10.3390/nu12051233. |
[4] | SZOT J O, CAMPAGNOLO C, CAO Y, et al. Bi-allelic mutations in NADSYN1 cause multiple organ defects and expand the genotypic spectrum of congenital NAD deficiency disorders[J]. Am J Hum Genet, 2020, 106(1):129-136. doi: 10.1016/j.ajhg.2019. 12.006. |
[5] | LIN J, ZHAO L, ZHAO S, et al. Disruptive NADSYN1 variants implicated in congenital vertebral malformations[J]. Genes (Basel), 2021, 12(10):1615. doi: 10.3390/genes12101615. |
[6] | MOHAMMAD R H, POURHOSSEINGHOLI M A, YADEGAR A, et al. High-resolution melt curve analysis:A real-time based multipurpose approach for diagnosis and epidemiological investigations of parasitic infections[J]. Comp Immunol Microbiol Infect Dis, 2019, 67:101364. doi: 10.1016/j.cimid.2019.101364. |
[7] | MUTLU M, CAYIR A, CAYIR Y, et al. Vitamin D and hyperbilirubinaemia in neonates[J]. Hong Kong J Paediatr, 2013, 18:77-81. |
[8] | ALETAYEB S M, DEHDASHTIYAN M, AMINZADEH M, et al. Comparison between maternal and neonatal serum vitamin D levels in term jaundiced and nonjaundiced cases[J]. J Chin Med Assoc, 2016, 79(11):614-617. doi: 10.1016/j.jcma.2016.05.008. |
[9] | MEHRPISHEH S, MEMARIAN A, MAHYAR A, et al. Correlation between serum vitamin D level and neonatal indirect hyperbilirubinemia[J]. BMC Pediatr, 2018, 18(1):178. doi: 10.1186/s12887-018-1140-9. |
[10] | 盛晓阳, 向伟, 王卫平, 等. 儿童微量营养素缺乏防治建议[J]. 中华儿科杂志, 2010, 48(7):502-509. |
SHENG X Y, XIANG W, WANG W P, et al. Recommendations for prevention and treatment of micronutrient deficiency in children[J]. Chin J Pediatr, 2010, 48(7):502-509. doi: 10.3760/cma.j.issn.0578-1310.2010.07.006. | |
[11] | WANG TJ, ZHANG F, RICHARDS J B, et al. Common genetic determinants of vitamin D insufficiency:a genome-wide association study[J]. Lancet, 2010, 376(9736):180-188. doi: 10.1016/S0140-6736(10)60588-0. |
[12] | BERGMANN A U, THORKELSSON T. Incidence and risk factors for severe hyperbilirubinemia in term neonates[J]. Laeknabladid, 2020, 106(3):139-143. doi: 10.17992/lbl.2020.03.473. |
[13] | 赵惠琴, 张新华. 新生儿高胆红素血症的病因分析和临床特点探讨[J]. 中国基层医药, 2015, 22(3):380-382. |
ZHAO H Q, ZHANG X H. Analysis of etiology and clinical characteristics of neonatal hyperbilirubinemia[J]. Chinese Journal of Primary Medicine and Pharmacy, 2015, 22(3):380-382. doi: 10.3760/cma.j.issn.1008-6706.2015.03.020 | |
[14] | EZEAKA C V, UGWU R O, MUKHTAR-YOLA M, et al. Pattern and predictors of maternal care-seeking practices for severe neonatal jaundice in Nigeria:A multi-centre survey[J]. BMC Health Serv Res, 2014, 4:192. doi: 10.1186/1472-6963-14-192. |
[15] | LIU Y, SUN X, WANG Y, et al. Evaluation of associated markers of neonatal pathological jaundice due to bacterial infection[J]. Iran J Public Health, 2021, 50(2):333-340. doi: 10.18502/ijph.v50i2. 5394. |
[16] | DEMIRARAN Y, ALBAYRAK M, SEKER I S, et al. Effect of anesthesiological strategies on neonatal bilirubin levels during cesarean section:a prospective and randomized trial[J]. Arch Gynecol Obstet, 2011, 284(5):1059-1065. doi: 10.1007/s00404-010-1783-8. |
[17] | GOURLEY G R, LI Z, KREAMER B L, et al. A controlled,randomized,double-blind trial of prophylaxis against jaundice among breastfed newborns[J]. Pediatrics, 2005, 116(2):385-391. doi: 10.1542/peds.2004-1807. |
[18] | CHIU Y W, CHENG S W, YANG C Y, et al. Breastfeeding in relation to neonatal jaundice in the first week after birth:parents' perceptions and clinical measurements[J]. Breastfeed Med, 2021, 16(4):292-299. doi: 10.1089/bfm.2020.0293. |
[19] | HUDSON J A, CHARRON E, MAPLE B, et al. Baby-friendly hospital initiative is associated with lower rates of neonatal hyperbilirubinemia[J]. Breastfeed Med, 2020, 15(3):176-182. doi: 10.1089/bfm.2019.0220. |
[20] | WANG H Q, KONG E L, ZHANG X, et al. Folic acid alleviates jaundice of phenylhydrazine(PHA)-induced neonatal rats by reducing Lys-homocysteinylation of albumin[J]. Cell Biol Toxicol, 2021, 37(5):679-693. doi: 10.1007/s10565-021-09602-3. |
[21] | PÉREZ-LÓPEZ F R, PASUPULETI V, MEZONES-HOLGUIN E, et al. Effect of vitamin D supplementation during pregnancy on maternal and neonatal outcomes:a systematic review and meta-analysis of randomized controlled trials[J]. Fertil Steril, 2015, 103(5):1278-1288.e4. doi: 10.1016/j.fertnstert.2015.02.019. |
[22] | MOON R J, DAVIES J H, COOPER C, et al. Vitamin D,and maternal and child health[J]. Calcif Tissue Int, 2020, 106(1):30-46. doi: 10.1007/s00223-019-00560-x. |
[23] | JIANG X, O'REILLY P F, ASCHARD H, et al. Genome-wide association study in 79,366 European-ancestry individuals informs the genetic architecture of 25-hydroxyvitamin D levels[J]. Nat Commun, 2018, 9(1):260. doi: 10.1038/s41467-017-02662-2. |
[24] | ALAYLİOĞLU M, DURSUND E, GENC G, et al. Genetic variants of vitamin D metabolism-related DHCR7/NADSYN1 locus and CYP2R1 gene are associated with clinical features of Parkinson’s disease[J]. Int J Neurosci, 2022, 132(5):439-449. doi: 10.1080/00207454.2020.1820502. |
[25] | LIBUDA L, NAARESH R, LUDWIG C, et al. A mendelian randomization study on causal effects of 25(OH)vitamin D levels on attention deficit/hyperactivity disorder[J]. Eur J Nutr, 2021, 60(5):2581-2591. doi: 10.1007/s00394-020-02439-2. |
[26] | LIU H, JIANG X, QIAO Q, et al. Association of circulating 25-Hydroxyvitamin D and its related genetic variations with hepatocellular carcinoma incidence and survival[J]. Ann Transl Med, 2020, 8(17):1080. doi: 10.21037/atm-20-1637. |
[27] | LIU X, WU P, SHEN L, et al. DHCR7 rs12785878 T>C polymorphism is associated with an increased risk of early onset of Alzheimer's disease in Chinese population[J]. Front Genet, 2021, 12:583695. doi: 10.3389/fgene.2021.583695. |
[28] | DENNERY P A, WENG Y H, STEVENSON D K, 等. 血红素加氧酶:一种血红素代谢酶及其近况[J]. 中国当代儿科杂志, 2001, 3(4):350-351,366. |
DENNERY P A, WENG Y H, STEVENSON D K, et al. Heme oxygenase:a heme cababolic enzyme and more[J]. Chin J Contemp Pediatr, 2001, 3(4):350-351,366. | |
[29] | IRIE J, INAGAKI E, FUJITA M, et al. Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men[J]. Endocr J, 2020, 67(2):153-160. doi: 10.1507/endocrj.EJ19-0313. |
[1] | 曹君阳, 马春星, 刘志娜. 维生素及叶酸水平对妊娠期糖尿病并发子痫前期的预测价值[J]. 天津医药, 2024, 52(12): 1278-1282. |
[2] | 陈灵芝, 钟开义, 陈立国. MTHFR基因启动子甲基化与糖尿病肾病发病的关系研究[J]. 天津医药, 2022, 50(6): 633-638. |
[3] | 李旭东, 马勇, 邓润鹏, 苍雪玉, 吴飞燕, 李永涛, 金海峰△. 黄芪总皂苷对缺氧性肺动脉高压作用探讨[J]. 天津医药, 2021, 49(3): 264-268. |
[4] | 张宇昕, 盖聪, 杨璐平, 马浩洁, 张锦坤, 孙红梅, 胡蝶. MTHFR C677T基因多态性与孤独症谱系障碍易感性关系的Meta分析 #br#[J]. 天津医药, 2021, 49(2): 212-218. |
[5] | 贾新转, 王聪敏, 刘二缓, 张娜, 魏兰. 继发性不孕患者卵泡液25-(OH)D水平与IVF卵母细胞发育关系的研究#br#[J]. 天津医药, 2020, 48(12): 1187-1192. |
[6] | 罗影, 左中夫, 张俏, 薛坤, 刘畅, 闵连秋. 蜂胶乙醇提取物通过p38 MAPK/NOX4信号通路对1型 糖尿病大鼠肾脏的保护作用[J]. 天津医药, 2020, 48(11): 1040-1044. |
[7] | 王蕾, 孙凤姣, 李旭. 缺乏维生素D受体激活及CYP27B1代谢调控在心肾综合征中的作用[J]. 天津医药, 2018, 46(9): 1013-1018. |
[8] | 刘志平, 张金华, 王湘宁, 徐莹. 维生素D对非酒精性脂肪性肝病患者铁代谢的影响[J]. 天津医药, 2018, 46(12): 1316-1318. |
[9] | 齐丽△, 田永红. 维生素D与社区获得性肺炎病情程度的相关性研究[J]. 天津医药, 2018, 46(11): 1189-1192. |
[10] | 宋琪 1,翁晓芬 1,董婷 1,许莉敏 1,谢燕 1,秦正红 2. NADPH 对人脐静脉内皮细胞缺糖缺氧复灌损伤早期的保护作用[J]. 天津医药, 2017, 45(9): 907-911. |
[11] | 唐亮1,2,鲍玉成2,高瑞霄3,韩臣富2,孙晓晨2,张文龙2,冯世庆1△. 维生素D 缺乏与脊柱结核易感性的关系研究[J]. 天津医药, 2016, 44(12): 1492-1495. |
[12] | 曾繁睿,张令晖,沙杭,刘勇谋,吴娟. 成人哮喘血清维生素D 水平与肺功能相关因素分析[J]. 天津医药, 2015, 43(12): 1416-1419. |
[13] | 王转锁,宋钦华,吴月平,陈竑,谭丽玲,孙胜花. Graves病患者骨代谢指标的变化[J]. , 2014, 42(7): 683-686 . |
[14] | 孙莲莲,李长春,姜忠敏,盛凤. 碳酸饮料对乳恒牙更替期牙齿健康的影响[J]. , 2014, 42(6): 565-568 . |
[15] | 孙莲莲. 1,25(OH)2D3在牙乳头干细胞成骨分化期的作用研究[J]. , 2014, 42(5): 421-423 . |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||